May 28 2012
Tulane University Hospital, New Orleans, LA, USA will in May start a
prospective trial in Kidney Transplantation investigating the potential
of cross match XM-ONE® as part of the risk assessment of their patients.
"It is our belief that patients at higher risk for rejection can be
identified using XM-ONE® technology" says Professor Joseph Buell, chief
of surgery at Tulane. "Earlier identification of at risk patients prior
to a clinically relevant rejection will allow us to modify our
surveillance program and immunosuppression. In order to evaluate the
potential of this test within our traditionally challenging population
we started a baseline evaluation of XM-ONE®", he continues.
The study at Tulane will include 50 contiguous Caucasian and 50
contiguous African American renal transplant recipients and the patients
will be tested with XM-ONE® both before transplantation and at a
follow-up 6 months post transplantation.
"This is clearly encouraging for us", says Anders Karlsson, CEO of
Allenex. "It further strengthens our belief that XM-ONE® has a role in
the pre transplant risk assessment. The initiative of Prof. Buell and
the transplant team at Tulane to also include post-transplant evaluation
to the repertoire makes this even more exciting", he ends.
Source:
Tulane University Hospital
Ultra-processed foods raise chronic kidney disease risk, study shows